Active — Not RecruitingNot Applicable

Sofosbuvir/Velpatasvir/Voxilaprevir Salvage Therapy in Hepatitis C Patients Who Relapsed After DAA Treatment

China200 participantsStarted 2022-01-01

Plain-language summary

This multicenter study evaluates the effectiveness and safety of a 12-week regimen of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C who relapsed after prior direct-acting antiviral therapy. The study assesses the rate of sustained virologic response after treatment, along with changes in liver function and overall safety. It also explores whether clinical factors such as liver cirrhosis, viral genotype, and the use of ribavirin influence treatment outcomes, aiming to better define this regimen as a salvage therapy option.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥18 years at the time of enrollment
✓. Confirmed chronic hepatitis C virus (HCV) infection
✓. Documented virologic relapse after prior direct-acting antiviral (DAA) therapy
✓. Detectable HCV RNA at screening
✓. Received or planned to receive a 12-week regimen of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) as salvage therapy
✓. Willing and able to provide written informed consent

Exclusion criteria

✕. Pregnant or breastfeeding women
✕. Participation in another interventional clinical study during the study period

What they're measuring

Sustained Virologic Response at 12 Weeks After Treatment (SVR12)

Timeframe: 12 weeks after end of treatment

Trial details

NCT IDNCT07565948

SponsorXiangya Hospital of Central South University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-12-31

View on ClinicalTrials.gov More Hepatitis C Virus (HCV) trials